BTG outlines strategy for building sustainability
This article was originally published in Scrip
BTG CEO Louise Makin believes pursuit of the company's three-pronged strategy will return the company to sustainable profitability. Having reported three consecutive years of profit through to 31 March 2008, the UK-based specialty pharma company reported losses in 2009 and 2011, but has just announced pre-tax profits of £23 million, against the £10.8 million loss in the year ending 31 March 2011. Concomitantly, revenue increased by 77% to £197 million compared with £111 million in the same period last time.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.